Related Experiment Video
Updated: Jun 3, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
[The role of adjuvant chemotherapy in operable non-small cell lung cancer]
Xiangtao Yan1, Hui Zhu, Huijuan Wang
1Depatment of Medical Oncology, Henan Tumor Hosipital, Zhengzhou 450000, China.
Abstract:
Postoperative recurrence is the main cause of primary treatment failure in the resectable non-small cell lung cancer (NSCLC). Systematic treatments should be taken to decrease the recurrence. Adjuvant chemotherapy, including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and targeted therapy, is a widely used in this area. In this review, we summarize the clinical trials and meta-analysis related to the adjuvant chemotherapy and targeted therapy in patients with early stage NSCLC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
